Digest Network Come funziona
Network
/
Società
En
Non verificato

Enterome

Di cosa scriviamo

Annunci EconomiciBiotecnologiaEventiFarmaceuticaMedicina Salute Benessere

13 comunicati stampa

Guarda tutti i comunicati
14/06/2026
Biotecnologia
Medicina Salute Benessere
Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
27/05/2026
Biotecnologia
Medicina Salute Benessere
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
11/05/2026
Biotecnologia
Medicina Salute Benessere
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
28/01/2026
Biotecnologia
Medicina Salute Benessere
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
08/12/2025
Biotecnologia
Medicina Salute Benessere
Enterome presents strengthened interim Phase 2 results for lead OncoMimics™ immunotherapy EO2463 to treat follicular lymphoma at ASH
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
01/12/2025
Biotecnologia
Medicina Salute Benessere
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
12/11/2025
Biotecnologia
Medicina Salute Benessere
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
15/10/2025
Biotecnologia
Medicina Salute Benessere
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
22/06/2025
Biotecnologia
Annunci Economici
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0
11/06/2025
Biotecnologia
Annunci Economici
Finanza
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Fonte
Enterome
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0